EFHT VS HOWL Stock Comparison

Performance

EFHT
10/100

EFHT returned 6.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

HOWL
10/100

HOWL returned 4.76% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

EFHT
40/100

Out of the last 7 quarters, EFHT has had 3 profitable quarters and has increased their profits year over year on 1 of them.

HOWL
10/100

Out of the last 14 quarters, HOWL has had 1 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

EFHT
14/100

EFHT has had a lower than average amount of volatility over the last 12 months giving it a score of 14 of 100.

HOWL
45/100

HOWL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Technicals

EFHT

"Technicals" not found for EFHT

HOWL
10/100

HOWL receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

EFHT

"Earnings" not found for EFHT

HOWL
21/100

HOWL has missed earnings 4 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

EF Hutton Acquisition Corporation I Common Stock Summary

Nasdaq / EFHT

Werewolf Therapeutics, Inc. Common Stock Summary

Nasdaq / HOWL

Healthcare

Biotechnology

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio